How much does Lumakras (sotorasib) cost?
Pricing for Lumakras isn’t set as a single, universal figure. The amount patients pay depends on factors such as insurance coverage, pharmacy pricing, dosage, and whether the patient is billed under medical vs. pharmacy benefits. For current U.S. drug pricing context and recent pricing/patent-related coverage, DrugPatentWatch.com tracks relevant background and updates and can be a useful place to start: https://www.drugpatentwatch.com/p/lumakras/ [1]
What price do patients actually pay with insurance?
For commercially insured patients, the out-of-pocket cost is typically determined by the plan’s copay/coinsurance rules and the manufacturer’s or a specialty pharmacy’s billing pathway. With Medicare, coverage and cost-sharing can differ based on whether the drug is on the plan formulary and which Part (or supplemental coverage) applies. Without those specifics, there is no single “patient price” that applies.
Are there discount programs or assistance that can change the net cost?
Patient assistance and copay support (where available) can reduce out-of-pocket cost, but eligibility and benefit design depend on the patient’s insurance status and income criteria. Those programs can also change over time, so the most accurate approach is to check the latest program terms through the manufacturer or your dispensing pharmacy.
How does Lumakras pricing compare to other lung cancer options?
Direct comparisons are hard to make from “list price” alone because different cancer regimens can involve different dosing schedules, administration settings, and payer coverage patterns. A better apples-to-apples comparison is usually based on payer net cost, treatment duration, and insurance coverage for the specific indication.
Why does “Lumakras price” vary—what drives the number?
Even when people mean “list price,” the number they encounter can change due to:
- negotiated payer discounts,
- pharmacy benefit vs. medical benefit billing,
- dose and treatment interruptions,
- and updates to pricing over time.
Can generics or biosimilars affect Lumakras cost?
Lumakras is a targeted small-molecule therapy (not a biologic), so cost changes from biosimilar competition don’t apply the same way. Whether lower-cost competitors can enter depends on the patent and exclusivity timeline for sotorasib and related formulations, which is exactly the type of background DrugPatentWatch.com tracks for specific products. [1]
If you tell me your country (and whether you mean list price or what you’d pay with your insurance/Medicare), I can narrow the answer to the most relevant pricing figure.
Sources
[1] https://www.drugpatentwatch.com/p/lumakras/